Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349106 | 0.86 | DYRK1A (0.70) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL27904850 | 0.82 | MCHR1 (0.48) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL16252867 | 0.81 | KEAP1 (0.50) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL761997 | 0.81 | DYRK1A (0.49) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL24231582 | 0.80 | MCHR1 (0.46) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL29272576 | 0.80 | MCHR1 (0.52) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL22166710 | 0.78 | SSTR4 (0.46) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL19950935 | 0.78 | SSTR4 (0.49) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL19465707 | 0.78 | SSTR4 (0.46) | MCHR1CYP1A2METAP2DYRK1AKEAP1 | |
| SCHEMBL16473235 | 0.76 | TGFBR1 (0.56) | MCHR1CYP1A2METAP2DYRK1ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| EP-4549442-A1 | PRMT5 INHIBITORS AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-119487041-A | PRMT5 inhibitor and application thereof | 上海赛岚生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2024-09-10 | — | — | US | disclosed |
| CN-117659010-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024046512-A2 | NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-03-07 | — | — | WO | disclosed |
| WO-2024002377-A1 | CLASS OF PRMT5 INHIBITORS AND USE THEREOF | 上海赛岚生物科技有限公司 | 2024-01-04 | — | — | WO | disclosed |
| CN-111867581-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | MCHR1 986/4885CYP1A2 1051/4885METAP2 4632/4885 |
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | MCHR1 2836/4885CYP1A2 2383/4885METAP2 2435/4885 |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | MCHR1 4521/4885CYP1A2 3059/4885METAP2 358/4885 |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | MCHR1 4521/4885CYP1A2 3059/4885METAP2 358/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | MCHR1 2836/4885CYP1A2 2383/4885METAP2 2435/4885 |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | MCHR1 4706/4885CYP1A2 4679/4885METAP2 2913/4885 |
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | PRMT5, PRMT1, PRMT6 | MCHR1 3598/4885CYP1A2 2104/4885METAP2 2318/4885 |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | MCHR1 199/4885CYP1A2 1401/4885METAP2 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.